The Clorox Company

NYSE:CLX Stock Report

Market Cap: US$10.9b

Clorox Future Growth

Future criteria checks 2/6

Clorox is forecast to grow earnings and revenue by 8.1% and 5.4% per annum respectively. EPS is expected to grow by 10.7% per annum. Return on equity is forecast to be 224.7% in 3 years.

Key information

8.1%

Earnings growth rate

10.68%

EPS growth rate

Household Products earnings growth5.4%
Revenue growth rate5.4%
Future return on equity224.70%
Analyst coverage

Good

Last updated04 May 2026

Recent future growth updates

Analysis Article • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...

Recent updates

Narrative Update • Apr 29

CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple

Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.
Seeking Alpha • Apr 28

Clorox: Reduced Complexity Paves The Way For Multiple Expansion

Summary Clorox is attractively valued after underperformance, offering a 5% dividend yield and normalization post-cyber attack and ERP disruptions. The recent Purell (GOJO) acquisition is set to be accretive to EBITDA and EPS by FY27, supporting top-line growth above the company's long-term algorithm. CLX trades at 14.5x FY27 EPS, with double-digit earnings growth and room for multiple expansion relative to peers, setting up 20% upside potential. Risks include high customer concentration, private label competition, and consumer value-seeking behavior, but strong cash flow supports deleveraging and dividend sustainability. Read the full article on Seeking Alpha
Narrative Update • Apr 15

CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power

Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.
Narrative Update • Mar 31

CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power

Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.
Narrative Update • Mar 17

CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook

Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.
Narrative Update • Mar 03

CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power

Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.
Narrative Update • Feb 17

CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E

The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.
Narrative Update • Feb 03

CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple

Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.
Narrative Update • Jan 20

CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating

Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.
Narrative Update • Jan 05

CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating

Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.
Narrative Update • Dec 20

CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook

Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.
Narrative Update • Dec 05

CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery

Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.
Narrative Update • Nov 21

CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026

Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.
Analysis Article • Nov 12

Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet

Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...
Analysis Article • Nov 10

Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...
Narrative Update • Nov 06

CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026

Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.
Narrative Update • Oct 23

Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook

Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.
Narrative Update • Oct 09

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.
Narrative Update • Aug 27

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.
Analysis Article • Aug 04

Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24

The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...
Analysis Article • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...
Analysis Article • Jul 16

Returns On Capital At Clorox (NYSE:CLX) Have Stalled

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Mar 29

Clorox: Reviving From Cyberattack; Initiate With 'Buy'

Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Clorox: A Wonderful Business I Would Like To Own At A Lower Price

Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking Alpha
Seeking Alpha • Nov 26

The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals

Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:CLX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20287,7968258481,0769
6/30/20277,5777828521,06112
6/30/20266,68459275876710
3/31/20266,760756380576N/A
12/31/20256,758755778984N/A
9/30/20256,771791636853N/A
6/30/20257,104810761981N/A
3/31/20257,0196948011,027N/A
12/31/20247,165457695923N/A
9/30/20247,469357669896N/A
6/30/20247,093280483695N/A
3/31/20247,209240570785N/A
12/31/20237,31080728944N/A
9/30/20237,035867941,000N/A
6/30/20237,3891499301,158N/A
3/31/20237,171748401,063N/A
12/31/20227,065435721951N/A
9/30/20227,041405678923N/A
6/30/20227,107462535786N/A
3/31/20227,108458563834N/A
12/31/20217,080247580869N/A
9/30/20217,231437620934N/A
6/30/20217,3417109451,276N/A
3/31/20217,5229231,3051,633N/A
12/31/20207,5241,2251,3831,677N/A
9/30/20207,1311,1511,3891,658N/A
6/30/20206,7219391,2921,546N/A
3/31/20206,3658709661,195N/A
12/31/20196,133816N/A1,041N/A
9/30/20196,157813N/A1,004N/A
6/30/20196,214820N/A992N/A
3/31/20196,278796N/A1,003N/A
12/31/20186,244790N/A1,101N/A
9/30/20186,187841N/A975N/A
6/30/20186,124823N/A976N/A
3/31/20186,080808N/A962N/A
12/31/20176,040799N/A922N/A
9/30/20176,030716N/A958N/A
6/30/20175,973703N/A865N/A
3/31/20175,926666N/A813N/A
12/31/20165,875653N/A863N/A
9/30/20165,814654N/A801N/A
6/30/20165,761648N/A778N/A
3/31/20165,718672N/A826N/A
12/31/20155,693657N/A782N/A
9/30/20155,693634N/A778N/A
6/30/20155,655606N/A874N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLX's forecast earnings growth (8.1% per year) is above the savings rate (3.5%).

Earnings vs Market: CLX's earnings (8.1% per year) are forecast to grow slower than the US market (16.4% per year).

High Growth Earnings: CLX's earnings are forecast to grow, but not significantly.

Revenue vs Market: CLX's revenue (5.4% per year) is forecast to grow slower than the US market (11.4% per year).

High Growth Revenue: CLX's revenue (5.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLX's Return on Equity is forecast to be very high in 3 years time (224.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 17:27
End of Day Share Price 2026/05/07 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

The Clorox Company is covered by 35 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John StaszakArgus Research Company
Lauren LiebermanBarclays
Lauren LiebermanBarclays